Drug intelligence / Profile preview

gusperimus + glucocorticoids

Development stage
Preclinical
Lead developer
Nippon Kayaku
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Administration
Oral (for Most Glucocorticoids), Subcutaneous (gusperimus Has Been Administered Subcutaneously In Clinical Studies)[2]
01

Overview

Gusperimus + glucocorticoids is a combination therapy consisting of gusperimus, an immunosuppressive agent, and glucocorticoids, a class of corticosteroid hormones. Gusperimus (also known as 15-deoxyspergualin) acts by modulating immune responses through effects on various arms of the immune system, including inhibition of lymphocyte proliferation and function[1][2][6]. Glucocorticoids exert broad anti-inflammatory and immunosuppressive effects primarily via binding to the glucocorticoid receptor, leading to suppression of pro-inflammatory gene expression. This combination has been investigated for use in autoimmune diseases such as granulomatosis with polyangiitis (Wegener's granulomatosis), where it aims to induce remission while reducing long-term exposure to more toxic agents like cyclophosphamide[2][5][8].

02

Targets

GR (Glucocorticoid receptor)HSPA8 (Heat shock cognate 71 kDa protein)

Beyond the preview

Go deeper on gusperimus + glucocorticoids.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on gusperimus + glucocorticoids.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call